Physician profile
John Nguyen
NPI 1457556003
$166,692.71
in general payments reported to CMS, 2019-2025
18 companies · $66K in 2025
The $66K reported for 2025 was more than what 99% of Ophthalmic Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $299).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,799 · 2020: $3,089 · 2021: $6,187 · 2022: $13K · 2023: $32K · 2024: $40K · 2025: $66K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $47K · Honoraria: $43K · Travel and Lodging: $21K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $9,090 · Consulting Fee: $8,350 · Food and Beverage: $7,275 · Education: $3,010.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $46,600.00 |
| Honoraria | $42,750.00 |
| Travel and Lodging | $20,510.37 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $9,090.00 |
| Consulting Fee | $8,350.00 |
| Food and Beverage | $7,274.97 |
| Education | $3,010.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $68,046.74 | 2024-2025 | Tepezza |
| Horizon Therapeutics Plc | $60,131.58 | 2019-2023 | Tepezza |
| Kerecis Limited | $19,019.06 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Surgiclose, Kerecis Omega3 Surgiclose |
| Ani Pharmaceuticals, INC. | $18,330.22 | 2024-2025 | Purified Cortrophin Gel, Iluvien |
| Biotissue Holdings INC. | $230.51 | 2025 | |
| Organogenesis INC. | $185.95 | 2025 | Puraply Wound Matrix, Affinity, Apligraf |
| Musculoskeletal Transplant Foundation INC. | $175.55 | 2022-2024 | |
| Galderma Laboratories, L.P. | $107.64 | 2019 | |
| Ivantis, INC | $96.20 | 2021 | |
| Mallinckrodt Enterprises LLC | $84.07 | 2019 | |
| Sight Sciences, INC. | $82.94 | 2025 | Omni Surgical System, Sion Surgical Instrument |
| Stryker Corporation | $73.38 | 2024 | Na |
| Genentech USA, INC. | $57.01 | 2019 | |
| Alcon Vision LLC | $29.66 | 2025 | Centurion |
| Merz Pharmaceuticals, LLC | $26.08 | 2025 | Xeomin |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $16.12 | 2024 | Trumatch |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.